Kidney Failure

PHILADELPHIA — County-level structural racism may be a statistically significant predictor of death among people with kidney failure, according to research presented at ASN Kidney Week.

The FDA has granted fast track designation for KYV-101, an autologous, fully human CD19 chimeric antigen receptor T-cell product candidate, to treat myasthenia gravis.

Using more stringent algorithms to define chronic kidney disease stage G4 may lead to lower estimates of disease incidence and a higher risk of kidney failure, researchers found.

Focal segmental glomerulosclerosis-attributed kidney failure may be linked with significant clinical and economic burdens, according to a recently published study.

A reexamination of factoring race into clinical equations for patient care will require changes at each step of the algorithm life cycle, according to an expert.

Long-term use of the potassium binder patiromer may improve clinical outcomes among patients with chronic kidney disease and hyperkalemia, according to a study.

PHILADELPHIA — Sparsentan was shown to be safe and well-tolerated, and reduced proteinuria in adults with IgA nephropathy, according to studies presented at ASN Kidney Week.

PHILADELPHIA — Treating hyperkalemia with Lokelma (sodium polystyrene sulfonate, AstraZeneca) increased odds of patients maintaining renin-angiotensin-aldosterone system inhibitors therapy, a speaker said.

The FDA has approved DefenCath, a catheter lock solution of taurolidine and heparin by CorMedix Inc., for adults with kidney failure on chronic hemodialysis, according to a press release.

PHILADELPHIA — Researchers presented data at ASN Kidney Week from a prediction model that can forecast all-cause mortality in adults with advanced chronic kidney disease.